Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Norah J. Shire"'
Autor:
Norah J Shire, Alyssa B Klein, Asieh Golozar, Jenna M Collins, Kathy H Fraeman, Beth L Nordstrom, Robert McEwen, Todd Hembrough, Naiyer A Rizvi
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0238358 (2020)
BackgroundMutations in STK11 (STK11m) and frequently co-occurring KRAS mutations (KRASm/STK11m) are associated with poor survival in metastatic NSCLC (mNSCLC) immuno-oncology trials. There are limited data regarding the prognostic significance of the
Externí odkaz:
https://doaj.org/article/a5de3eaa4070440fa054983d2d067b68
Autor:
Elizabeth Hedgeman, Jon P. Fryzek, Lars Pedersen, Deirdre Cronin-Fenton, Mette Nørgaard, Torben Riis Rasmussen, Naimisha Movva, Tapashi Dalvi, Stephen Hamilton-Dutoit, Hanh Hansen, Anders Mellemgaard, Norah J. Shire
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, 16892 . https://doi.org/10.1038/s41598-021-96486-2
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, pp. 16892 . https://doi.org/10.1038/s41598-021-96486-2
Scientific Reports
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, 16892 . https://doi.org/10.1038/s41598-021-96486-2
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, pp. 16892 . https://doi.org/10.1038/s41598-021-96486-2
Scientific Reports
Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c714e5100877d9c2cba31cc1cb53eae7
https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9
https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9
Autor:
Suresh Senan, Norah J. Shire, H. Jiang, Yuanbin Chen, Wenliang Yao, Gabriel Mak, Gyeong Won Lee, Byoung Chul Cho, Isamu Okamoto, Seiji Niho
Publikováno v:
Clinical Lung Cancer, 21(2), e84-e88. Elsevier
Senan, S, Okamoto, I, Lee, G-W, Chen, Y, Niho, S, Mak, G, Yao, W, Shire, N, Jiang, H & Cho, B C 2020, ' Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer : The ADRIATIC Study ', Clinical Lung Cancer, vol. 21, no. 2, pp. e84-e88 . https://doi.org/10.1016/j.cllc.2019.12.006
Senan, S, Okamoto, I, Lee, G-W, Chen, Y, Niho, S, Mak, G, Yao, W, Shire, N, Jiang, H & Cho, B C 2020, ' Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer : The ADRIATIC Study ', Clinical Lung Cancer, vol. 21, no. 2, pp. e84-e88 . https://doi.org/10.1016/j.cllc.2019.12.006
Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. The standard-of-care therapy comprises curative-intent platinum-based chemotherapy with concurrent radiotherapy (cCRT), which can be followed by prophylactic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4e1a2029ea7ac2e2ed3f598b3dd0427
http://www.scopus.com/inward/record.url?scp=85077926641&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85077926641&partnerID=8YFLogxK
Autor:
Iain P. Fraser, Larissa Wenning, Eric Mangin, Bonnie J. Howell, Christine Fandozzi, Jill Maxwell, W. Gao, Radha Railkar, Kristien Van Dyck, Chris Chung, Norah J. Shire, Andrew H. Talal, Melanie Anderson, Luzelena Caro, Serghei Popa, Andrea L. Webber, André M. M. Miltenburg, S. Aubrey Stoch
Publikováno v:
Clinical Pharmacology & Therapeutics. 107:1325-1333
Fine-needle aspiration (FNA) for serial hepatic sampling may be an efficient and less invasive alternative to core needle biopsy (CNB), the current standard for liver tissue sampling. In this randomized, open-label trial in 31 participants with hepat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8504ae5549bfbd91fd93b738af6db4b
https://doi.org/10.1002/cpt.1737
https://doi.org/10.1002/cpt.1737
Autor:
Fabiola Cecchi, Natasha Viglianti, Marlon Rebelatto, Norah J Shire, Simon T Barry, Tsveta Milenkova, Elizabeth Croydon, Danielle Carroll, J Carl Barrett
Publikováno v:
Journal of Clinical Oncology. 41:194-194
194 Background: Although regularly used in breast and gastric cancer, HER2 testing is not routinely performed in colorectal cancer (CRC). Immunohistochemistry (IHC) and in situ hybridization (ISH) scoring have not been optimized for assessment of HER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc4fdeb8984004b7f9ae9d9699ee6f8b
https://doi.org/10.1200/jco.2023.41.4_suppl.194
https://doi.org/10.1200/jco.2023.41.4_suppl.194
Autor:
Mette Nørgaard, Torben Riis Rasmussen, Norah J. Shire, Hanh Hansen, Anders Mellemgaard, Anita Midha, Jill Walker, Elizabeth Hedgeman, Lars Pedersen, Tapashi Dalvi, Deirdre Cronin-Fenton, Stephen Hamilton-Dutoit, J. Rigas, Anne-Marie Boothman, Jon P. Fryzek
Publikováno v:
Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A-M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, pp. 101976 . https://doi.org/10.1016/j.canep.2021.101976
Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, 101976 . https://doi.org/10.1016/j.canep.2021.101976
Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, 101976 . https://doi.org/10.1016/j.canep.2021.101976
BACKGROUND: PD-L1 expression on tumor cells (TCs) or immune cells (ICs) may be used as a prognostic marker for survival in patients with NSCLC. We characterized PD-L1 expression on TCs or ICs in a patient cohort with NSCLC to determine associations b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46578e6da5a61a4e3e492aa29027f4dc
https://pure.au.dk/portal/da/publications/programmed-cell-death-ligand1-expression-and-survival-in-a-cohort-of-patients-with-nonsmall-cell-lung-cancer-receiving-firstline-through-thirdline-therapy-in-denmark(d9615987-9773-43dc-9b60-de7ac1e0059e).html
https://pure.au.dk/portal/da/publications/programmed-cell-death-ligand1-expression-and-survival-in-a-cohort-of-patients-with-nonsmall-cell-lung-cancer-receiving-firstline-through-thirdline-therapy-in-denmark(d9615987-9773-43dc-9b60-de7ac1e0059e).html
Autor:
Meina Liang, Norah J. Shire, Enass A. Abdel-hameed, Kenneth E. Sherman, Mark T. Esser, Mohamed T. Shata, Li Yu, Esther Song, Susan D. Rouster
Publikováno v:
Pathogens and Immunity, Vol 4, Iss 1, Pp 39-65 (2019)
Pathogens & immunity
Pathogens & immunity
Background: Hepatitis B virus (HBV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Due to their shared routes of transmission, approximately 10% of HIV-infected patients worldwide are chron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1068598a925adf58369b374fc804f2a
https://paijournal.com/index.php/paijournal/article/view/267
https://paijournal.com/index.php/paijournal/article/view/267
Autor:
Muslim Atiq, Norah J. Shire, Anna Barrett, Susan D. Rouster, Kenneth E. Sherman, Mohamed T. Shata
Publikováno v:
Emerging Infectious Diseases, Vol 15, Iss 3, Pp 479-481 (2009)
In the United States, the seroprevalence rate for hepatitis E virus (HEV) is ≈20%. This study examined HEV seroprevalence in persons with and without chronic liver disease. Our data indicate that HEV seropositivity is high in patients with chronic
Externí odkaz:
https://doaj.org/article/c247c17edcd84830a1e7838691d81583
Autor:
Marina Chiara Garassino, J.H. Ji, Nikunj Patel, Y. Chen, Jonathan W. Goldman, György Losonczy, Norah J. Shire, Galina Statsenko, Katsuyuki Hotta, Haiyi Jiang, Oleksandr Voitko, Libor Havel, D. Trukhin, Maximilian Hochmair, Peter J. Laud, Mikhail Dvorkin, A. Poltoratskiy, Niels Reinmuth, Luis Paz-Ares, Mustafa Ozguroglu
OZGUROGLU, MUSTAFA/0000-0002-8417-8628 WOS:000579504300008 PubMed ID: 32961445 Objectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf33c41b74bbe8b2dd8b0bf98d18cb3d
https://eprints.whiterose.ac.uk/166497/3/PIIS0169500220306000.pdf
https://eprints.whiterose.ac.uk/166497/3/PIIS0169500220306000.pdf
Autor:
A. Poltoratskiy, N. Byrne, Niels Reinmuth, S Ponce, H. Jiang, György Losonczy, A Kazarnowicz, M Özgüroğlu, Jonathan H. Goldman, Maximilian Hochmair, Jon Armstrong, D. Trukhin, J Alt, Norah J. Shire, Oleksandr Voitko, I. Bondarenko, Galina Statsenko, Y. Chen, Nikolay Conev, J Ho Li, Luis Paz-Ares, Libor Havel, Francesco Verderame, Katsuyuki Hotta
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4d1bb808a4e56d51b25b81aab851631
https://doi.org/10.1055/s-0039-3403350
https://doi.org/10.1055/s-0039-3403350